UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 options and sold 9,500 United Therapeutics common shares held by a trust under a 10b5-1 plan on August 25, 2026.

On August 25, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equivalent number of common shares, then immediately sold all 9,500 resulting shares in a series of open market transactions at weighted average prices between approximately $516.12 and $520.50 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The gross sale proceeds were roughly $4.9–5.0 million against an option exercise cost of about $1.3 million, implying a gain of roughly $3.5–3.7 million, while the reporting person continues to hold substantial indirect ownership in United Therapeutics common stock through multiple family trusts and other accounts, as well as remaining stock options expiring in 2027.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000128

Alert Tier

7